ImmunoGen Inc (IMGN) Forecast, Price Target & Analyst Ratings

Q: What do analysts expect the price target to be for ImmunoGen Inc (IMGN)?

19 analysts have analysed IMGN and the average price target is 31.69 USD. This implies a price increase of 1.46% is expected in the next year compared to the current price of 31.23.

Q: When does ImmunoGen Inc (IMGN) report earnings?

ImmunoGen Inc (IMGN) will report earnings on 2024-04-26, after the market close.

NASDAQ:IMGN • US45253H1014

31.23 USD

0 (0%)

At close: Feb 9, 2024

31.24 USD

+0.01 (+0.03%)

After Hours: 2/9/2024, 8:00:02 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ImmunoGen Inc (IMGN).

Consensus Price Target

Price Target

$31.69

+ 1.46% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: Apr 26, 2024
Period: Q4 / 2023
EPS Estimate: $0.13
Revenue Estimate: 132.82M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

70.53%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$31.69

Upside

+ 1.46%

From current price of $31.23 to mean target of $31.69, Based on 19 analyst forecasts

Low

$16.16

Median

$31.62

High

$55.65

Price Target Revisions

1 Month

0.02%

3 Months

34.58%

Price Target Summary

19 Wall Street analysts provided a forecast for the next 12 months for IMGN. The average price target is 31.69 USD. This implies a price increase of 1.46% is expected in the next year compared to the current price of 31.23.

The average price target has been revised upward by 34.58% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

70.53%

IMGN was analyzed by 19 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about IMGN.

In the previous month the buy percentage consensus was at a similar level.

IMGN was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2023-12-04	Barclays	Downgrade	Overweight -> Equal-Weight
2023-12-04	Piper Sandler	Downgrade	Overweight -> Neutral
2023-12-01	Guggenheim	Downgrade	Buy -> Neutral
2023-12-01	BMO Capital	Downgrade	Outperform -> Market Perform
2023-12-01	Barclays	Downgrade	Overweight -> Equal-Weight
2023-12-01	Jefferies	Downgrade	Buy -> Hold
2023-11-30	HC Wainwright & Co.	Downgrade	Buy -> Neutral
2023-11-20	Goldman Sachs	Initiate	Neutral
2023-11-09	Deutsche Bank	Initiate	Buy
2023-11-03	HC Wainwright & Co.	Maintains	Buy -> Buy
2023-10-06	Oppenheimer	Initiate	Perform
2023-09-13	JP Morgan	Upgrade	Neutral -> Overweight
2023-08-29	HC Wainwright & Co.	Maintains	Buy -> Buy
2023-08-02	Barclays	Maintains	Overweight -> Overweight
2023-08-01	BMO Capital	Maintains	Outperform -> Outperform
2023-08-01	Canaccord Genuity	Maintains	Buy -> Buy
2023-08-01	HC Wainwright & Co.	Maintains	Buy -> Buy
2023-06-13	HC Wainwright & Co.	Maintains	Buy -> Buy
2023-06-12	Barclays	Maintains	Overweight
2023-06-12	Canaccord Genuity	Reiterate	Buy -> Buy
2023-06-06	Truist Securities	Maintains	Buy -> Buy
2023-06-05	Canaccord Genuity	Maintains	Buy -> Buy
2023-05-03	Piper Sandler	Upgrade	Neutral -> Overweight
2023-05-01	HC Wainwright & Co.	Reiterate	Buy
2023-03-02	HC Wainwright & Co.	Reiterate	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: Apr 26, 2024
Period: Q4 / 2023
EPS Estimate: $0.13
Revenue Estimate: 132.82M
Revenue Q2Q: 222.38%
EPS Q2Q: 157.18%
Number of Analysts: 16

Next Earnings Revisions

Revenue (1 Month)

0.00%

Revenue (3 Months)

2.12%

EPS (1 Month)

0.00%

EPS (3 Months)

10.27%

Next Earnings Summary

IMGN is expected to report earnings on 4/26/2024. The consensus EPS estimate for the next earnings is 0.13 USD and the consensus revenue estimate is 132.82M USD.

The next earnings revenue estimate has been revised upward by 2.12% in the past 3 months.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
Revenue YoY % growth	132.3M 60.75%	69.9M -47.17%	108.8M 55.65%	384.16M 253.09%	560.86M 46.00%	794.2M 41.60%	1.028B 29.44%	1.22B 18.68%	1.321B 8.28%	1.302B -1.44%	1.41B 8.29%
EBITDA YoY % growth	-18.8M 71.84%	-123.08M -554.68%	-219.12M -78.03%	-133.62M 39.02%	-82.62M 38.17%	223.44M 370.44%	483.45M 116.37%	634.43M 31.23%	N/A	N/A	N/A
EBIT YoY % growth	-20.9M 70.48%	-125.1M -498.56%	-220.9M -76.58%	15.273M 106.91%	116.72M 664.22%	277.81M 138.01%	466.61M 67.96%	615.47M 31.90%	734.1M 19.27%	700.5M -4.58%	785.76M 12.17%
Operating Margin	-15.80%	-178.97%	-203.03%	3.98%	20.81%	34.98%	45.39%	50.45%	55.57%	53.80%	55.73%
EPS YoY % growth	-0.28 60.56%	-0.67 -139.29%	-0.88 -31.34%	0.08 108.78%	0.38 396.25%	0.88 128.46%	1.44 64.94%	1.90 31.62%	2.13 12.17%	1.97 -7.66%	2.12 7.77%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q4 / 23	Q1 / 24	Q2 / 24	Q3 / 24	Q4 / 24	Q1 / 25	Q2 / 25	Q3 / 25	Q4 / 25	Q1 / 26	Q2 / 26	Q3 / 26
EPS Q2Q % growth	0.13 157.18%	0.04 123.91%	0.09 527.13%	0.11 10.74%	0.14 3.05%	0.12 220.00%	0.14 67.16%	0.20 84.21%	0.20 50.53%	0.22 83.33%	0.26 78.57%	0.28 35.00%
Revenue Q2Q % growth	132.82M 222.38%	126.87M 154.25%	138.43M 66.38%	141.89M 25.12%	155.95M 17.41%	156.57M 23.41%	170.71M 23.32%	194.75M 37.25%	210M 34.66%	215.22M 37.46%	227.46M 33.24%	232.56M 19.41%
EBITDA Q2Q % growth	30.753M 153.19%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	38.124M 163.97%	29.329M 169.17%	39.667M 1,044.45%	44.209M 70.03%	50.272M 31.86%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

44.14%

EPS Next 5 Year

32.99%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

109.41%

Revenue Next 5 Year

69.78%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

43.02%

EBIT Next 5 Year

35.85%

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ImmunoGen Inc / IMGN Forecast FAQ

What do analysts expect the price target to be for ImmunoGen Inc (IMGN)?

19 analysts have analysed IMGN and the average price target is 31.69 USD. This implies a price increase of 1.46% is expected in the next year compared to the current price of 31.23.

When does ImmunoGen Inc (IMGN) report earnings?

ImmunoGen Inc (IMGN) will report earnings on 2024-04-26, after the market close.

What are the consensus estimates for ImmunoGen Inc (IMGN) next earnings?

The consensus EPS estimate for the next earnings of ImmunoGen Inc (IMGN) is 0.13 USD and the consensus revenue estimate is 132.82M USD.

What is the expected long term growth rate for ImmunoGen Inc (IMGN)?

The expected long term growth rate for ImmunoGen Inc (IMGN) is 109.41%.

Analyst forecast overview

Forecast Snapshot